Beyond Air, Inc. (XAIR) News

Beyond Air, Inc. (XAIR): $0.45

0.04 (-7.31%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

F

Filter XAIR News Items

XAIR News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

XAIR News Highlights

  • XAIR's 30 day story count now stands at 3.
  • Over the past 6 days, the trend for XAIR's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about XAIR are DEC.

Latest XAIR News From Around the Web

Below are the latest news stories about BEYOND AIR INC that investors may wish to consider to help them evaluate XAIR as an investment opportunity.

Beyond Cancer™ Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or Subcutaneous Solid Tumors

No dose limiting toxicities were reported in the first cohort of ultra-high concentration of nitric oxide administered at 25,000 parts per million (PPM) Phase 1 study continues to recruit eligible patients in the next protocol defined cohort of 50,000 ppm in multiple centers in Israel HAMILTON, Bermuda, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) and a clinical stage biotechnology company developing ultra-high concentration nitric oxide

Yahoo | December 27, 2023

Beyond Air Independent Director Acquires 102% More Stock

Those following along with Beyond Air, Inc. ( NASDAQ:XAIR ) will no doubt be intrigued by the recent purchase of shares...

Yahoo | December 23, 2023

Insider Buying: CEO Steven Lisi Acquires 77,775 Shares of Beyond Air Inc

Beyond Air Inc (NASDAQ:XAIR) has witnessed a significant insider transaction on December 18, 2023, according to a recent SEC filing.

Yahoo | December 21, 2023

Beyond Air® To Participate in the 35th Annual Piper Sandler Healthcare Conference

GARDEN CITY, N.Y., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd. (“Beyond Cancer”)), today announced that Steve Lisi, Chairman and Chief Executive Offic

Yahoo | November 15, 2023

Beyond Air® Reports Financial Results for Second Quarter of Fiscal Year 2024

Provides fiscal year 2025 revenue guidance of $12 - $16 million US pilot trial of LungFit® PRO to treat viral community acquired pneumonia (VCAP) underway with data expected mid-calendar 2024 Beyond Cancer presents positive first-in-human data for intratumoral administration of ultra-high concentration nitric oxide (UNO) therapy demonstrating safety and evidence of immune system activation at the Society for Immunotherapy Conference (SITC) Submitted PMA supplement to FDA for the expansion of Lun

Yahoo | November 13, 2023

Beyond Cancer™ Presents Positive First-in-Human Clinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

First-in-human Phase 1 study demonstrates early clinical proof of concept Positive clinical biomarker data demonstrate evidence of immune system activation and the translation of the immunogenic response previously observed in preclinical studies Data represent the first successful administration of intratumoral UNO therapy Additional Phase 1 data for UNO expected in 2024 GARDEN CITY, N.Y. and HAMILTON, Bermuda, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, I

Yahoo | November 3, 2023

Beyond Air® Schedules Second Fiscal Quarter 2024 Financial Results Conference Call and Webcast

Call scheduled for Monday, November 13th at 4:30 pm Eastern TimeGARDEN CITY, N.Y., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd. (“Beyond Cancer”)), tod

Yahoo | October 19, 2023

Beyond Air® To Participate in the Truist Securities BioPharma Symposium

GARDEN CITY, N.Y., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd. (“Beyond Cancer”)), today announced that Steve Lisi, Chairman and Chief Executive Offic

Yahoo | October 17, 2023

Beyond Cancer™ Publishes Pre-Clinical Data in Cells Demonstrating that the Combination of Ultra-High Concentration Nitric Oxide (UNO) and Anti-mPD-1 Therapy Improves Tumor Regression Rates and Survival in Mice

Figure 1 PD-L1 Upregulation in CT26 and 4T1 Cells after In Vitro Exposure to UNO Figure 2 T-cell profiling in tumors of CT26 mice treated with UNO Figure 3 Myeloid cell profiling in CT26 tumors treated with UNO UNO therapy results in a more immunogenic tumor microenvironment (TME) as well as a systemic response that overcomes anti-PD-1 resistance First-in-human Phase 1 clinical study is ongoing with initial data expected to be released on November 3rd at the Society for Immunotherapy of Cancer (

Yahoo | October 17, 2023

Beyond Cancer™ Presents Positive Preclinical Data for Ultra-High Concentration Nitric Oxide (UNO) in Combination with Checkpoint Inhibitor Therapy During the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

50,000 or 100,000 ppm UNO alone or in combination with anti-mCTLA-4 more than tripled antigen specific central memory T-cell response versus anti-mCTLA-4 alone Pooled analysis of combination studies of 50,000 or 100,000 ppm UNO with anti-mPD-1 demonstrated more than a doubling in survival at Day 75 versus anti-mPD-1 alone Initial data from a Phase 1a, first-in-human study to be presented at the Society for Immunotherapy in Cancer (SITC) on November 3, 2023 GARDEN CITY, N.Y. and HAMILTON, Bermuda

Yahoo | October 16, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!